Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer

Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) is still one of the most lethal malignant diseases with a devastating 5‑year overall survival of only 4–5%. Indeed, long-term survival was not affected by the introduction of new systemic cytotoxic chemotherapies which remain the k...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieler, Markus, Unseld, Matthias, Bianconi, Daniela, Prager, Gerald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605578/
https://www.ncbi.nlm.nih.gov/pubmed/28989542
http://dx.doi.org/10.1007/s12254-017-0352-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605578/
https://www.ncbi.nlm.nih.gov/pubmed/28989542
http://dx.doi.org/10.1007/s12254-017-0352-2

Ejemplares similares